Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 third quarter ended June 30, 2025. The Company is hosting a conference call today, August 7, 2025, ...

ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Countdown Begins to November 18, 2025 PDUFA for Plozasiran Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is developing plozasiran for the ...

Monday announced that it has earned a $100 million milestone payment from Sarepta Therapeutics (NASDAQ:SRPT). The milestone ...

When Pasadena-based Arrowhead Pharmaceuticals Inc. signed a huge licensing and collaboration deal with Cambridge, ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q3 2024 Earnings Call Transcript August 8, 2024 Arrowhead Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1.37516 EPS ...

Sarepta Therapeutics' licensing partner Arrowhead Pharmaceuticals said on Wednesday it expects to receive near-term milestone ...

Arrowhead Pharmaceuticals, Inc. today announced that it is scheduled to participate in the following upcoming investor events:. BofA Securities 2025 Health Care Conference– May 13-15, 2025.

If so, you'll want to check out Arrowhead Pharmaceuticals (ARWR -0.97%). SVB Securities, a subsidiary of SVB Financial, recently gave the stock an upgrade to outperform and raised its price target.

What happened Shares of clinical-stage biotech company Arrowhead Pharmaceuticals (ARWR -0.97%) were up more than 17% Tuesday morning after the company released interim results from a phase 1/2 trial.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 7, 2025, at 4:30 p.m. ET to discuss its financial results for the fiscal ...

Arrowhead Pharmaceuticals, Inc. Vince Anzalone, CFA 626-304-3400 ir@arrowheadpharma.com Investors: LifeSci Advisors, LLC Brian Ritchie 212-915-2578 britchie@lifesciadvisors.com ...